January 24, 2022 03:27 PM EST
Pharma

GSK looks to stand out in the se­vere asth­ma space with at-home in­jec­tions for kids 6 to 11 years old

Nicole DeFeudis

Editor

Glax­o­SmithK­line’s block­buster Nu­cala may have been the first IL-5 drug to win mar­ket­ing ap­proval in se­vere asth­ma back in 2015, but new­er ri­vals like As­traZeneca …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times